Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Sorete Arbore, V. Cojocariu, R. Sorete Arbore (Iasi, Romania). DOTS PLUS versus non DOTS PLUS outcomes in MDRTB patients. Eur Respir J 2012; 40: Suppl. 56, 4289

Member's Comments

No comment yet.

Related content which might interest you: Outcomes of DOTS and DOTS Plus regimens implementing among patients with pulmonary tuberculosis relapses Source: Eur Respir J 2002; 20: Suppl. 38, 369s Year: 2002 Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013 Clinical profile of MDR-TB patients and their early response to DOTS PLUS: An Indian perspective Source: Annual Congress 2013 –Tuberculosis: clinical aspects Year: 2013 Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Cost-effectiveness of treating MDR-TB by adding delamanid to background regimens in Germany Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Tuberculosis-related deaths before and after the implementation of DOTS control program Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007 To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS) Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Population of bacteria in treatment of patients with tuberculosis by DOTS method Source: Eur Respir J 2001; 18: Suppl. 33, 175s Year: 2001 Effectiveness of integrated DOTS and DOTS-Plus in Latvia Source: Annual Congress 2004 - Management of tuberculosis Year: 2004 Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia Source: ERJ Open Res, 6 (1) 00030-2019; 10.1183/23120541.00030-2019 Year: 2020 The DOTS implementation in Lithuania Source: Eur Respir J 2002; 20: Suppl. 38, 216s Year: 2002 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 New approaches for evaluation of treatment effectiveness among patients with pulmonary TB under DOTS implemented conditions Source: Eur Respir J 2002; 20: Suppl. 38, 368s Year: 2002 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 MDR-TB treatment outcomes in HIV positive patients Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014